Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study

被引：0
|
作者：
Richardson, P. G.
Lonial, S.
Jakubowiak, A.
Jagannath, S.
Raje, N.
Avigan, D.
Ghobrial, I. M.
Knight, R.
Esseltine, D.
Anderson, K. C.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Winship Canc Inst, Atlanta, GA USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[4] St Vincents Comprehens Canc Ctr, New York, NY USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[7] Celgene Inc, Summit, NJ USA
[8] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8520
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
    Anderson, K. C.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Schlossman, R.
    Munshi, N.
    Knight, R.
    Esseltine, D.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study
    Anderson, K. C.
    Weller, E.
    Lonial, S.
    Jakubowiak, A. J.
    Jagannath, S.
    Raje, N. S.
    Avigan, D.
    Knight, R. D.
    Esseltine, D.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase II multisite study to evaluate efficacy and safety of single weekly administration of bortezomib (BZ) and dexmethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts)
    Munshi, N. C.
    Lee, S.
    Roodman, G. D.
    Behler, C.
    Kambhampati, S.
    Rose, M. G.
    Brophy, M. T.
    Houranieh, A.
    Esseltine, D.
    Lichtenstein, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).
    Lonial, Sagar
    Oriol, Albert
    Mateos, Maria-Victoria
    Rodriguez-Otero, Paula
    Bahlis, Nizar J.
    Bensinger, William
    Porkka, Kimmo
    Van De Donk, Niels
    Yiu, Wai
    Di Casoli, Carl
    Ervin-Haynes, Annette L.
    Zaki, Mohamed H.
    Vangsted, Annette
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
    Moreau, P.
    Palumbo, A. P.
    Stewart, A. K.
    Rajkumar, V.
    Jakubowiak, A. J.
    Halka, K.
    Goranov, S.
    Bumbea, H.
    Pendergrass, K. B.
    Lupu, A.
    Dimopoulos, A.
    Rocafiguera, A. O.
    Gandhi, J. G.
    Mihaylov, G.
    Masszi, T.
    Matous, J.
    Fonseca, G.
    Bryce, R.
    Siegel, D. S. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Phase II study of pegylated liposomal doxorubicin (PLD), low-dose dexamethasone (DEX), and lenalidomide (LEN) in patients with newly diagnosed (ND) multiple myeloma (MM)
    Baz, R.
    Hussein, M. A.
    Sullivan, D.
    Raychaudhuri, J.
    Ochoa, L.
    Kosakowski, K.
    Nardelli, L.
    Dalton, W. S.
    Alsina, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)
    Baz, Rachid
    Hussein, Mohamad A.
    Sullivan, Daniel
    Ochoa-Bayona, Jose-Leonel
    Hartley, Monique A.
    Shain, Kenneth
    Nishihori, Taiga
    Paleveda, Jennifer
    Kosakowski, Kara
    Dalton, William S.
    Alsina, Melissa
    BLOOD, 2010, 116 (21) : 1260 - 1260
  • [8] Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients
    Joseph, Nisha
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Dhodapkar, Madhav V.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2018, 132
  • [9] Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).
    Jakubowiak, Andrzej J.
    Griffith, Kent A.
    Dytfeld, Dominik
    Vesole, David H.
    Jagannath, Sundar
    Anderson, Tara B.
    Nordgren, Brian K.
    Detweiler-Short, Kristen
    Lebovic, Daniel
    Stockerl-Goldstein, Keith
    Jobkar, Terri L.
    Wear, Sandra Marija
    Al-Zoubi, Ammar
    Ahmed, Asra Z.
    Mietzel, Melissa A.
    Couriel, Daniel R.
    Kaminski, Mark Stefan
    Hussein, Mohamad A.
    Yeganegi, Homa
    Vij, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study
    Richardson, Paul
    Lonial, Sagar
    Jakubowiak, Andrzej
    Jagannath, Sundar
    Raje, Noopur S.
    Avigan, David
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Vesole, David H.
    Joyce, Robin
    Doss, Deborah
    Warren, Diane L.
    Hayes, Stephen W.
    Kaster, Sarah
    Delaney, Carol
    Lauria, Marisa
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert D.
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    BLOOD, 2008, 112 (11) : 41 - 41
12345